The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management attributes quarterly performance to the durability of the core PMO franchise and disciplined execution of expanded commercial initiatives for ELEVIDYS.

The company achieved GAAP and non-GAAP operating profitability, which management views as a critical foundation for independently funding their next-generation siRNA pipeline.

Strategic positioning is centered on a 'biology-first' approach, selecting specific delivery architectures like alpha v beta 6 integrin for muscle and transferrin receptors for the CNS to overcome tissue-specific barriers.

Management believes their siRNA platform offers a competitive advantage through catalytic multi-turnover activity, potentially providing deeper and more durable gene silencing than traditional antisense mechanisms.

The commercial strategy for ELEVIDYS has pivoted toward a 'balanced discussion' of benefit-risk, with early evidence of success seen in increased enrollment form activity from returning and new treatment sites.

Operational focus has shifted from footprint expansion to execution, specifically improving patient identification and strengthening healthcare provider confidence following the late 2024 label expansion.

Total net product revenue guidance for 2026 is narrowed to $1.2 billion to $1.3 billion, reflecting a trend toward the lower end of the original range due to the timing of the treatment journey.

Second-half 2026 revenue is expected to be modestly lower than the first half, as it reflects a period of lower enrollment activity prior to the full deployment of new commercial initiatives.

Management anticipates that the current improvement in enrollment forms will contribute more meaningfully to revenue in 2027, given the typical six-month lag from form submission to infusion.

Interim results from the MAD studies for FSHD (SRP-1001) and DM1 (SRP-1003) are expected in the second half of 2026, focusing on establishing the biological chain from tissue exposure to target knockdown.

The regulatory strategy for siRNA programs remains flexible, with the company preparing for either accelerated or traditional approval pathways depending on the evolving competitive landscape and data strength.

A $39 million litigation contingency charge was recorded in the quarter to potentially resolve outstanding patent claims.

Management noted that while competition for exon-skipping treatments is on the horizon, they expect any impact to be delayed until late 2027 due to the high hurdles of establishing reimbursement and support infrastructure.

The timeline for Cohort 8 (ENDEAVOR) 12-week data has moved to Q1 2027 because investigators are dosing patients sequentially rather than in parallel.

Guidance for collaboration and other revenue was revised upward by $75 million, primarily driven by higher contract manufacturing revenues from the Roche partnership.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

CEO Michael Severino emphasized that the DMD portfolio provides stable, durable revenue that allows the company to advance the siRNA programs independently without external financing.

He rejected the idea of separating the businesses, noting that the scientific expertise in neuromuscular disease is highly synergistic across both platforms.

Management expressed high confidence in maintaining PMO market share due to a decade of real-world evidence, 90% adherence rates, and established home-infusion support networks.

They noted that new competitors must overcome significant hurdles in reimbursement and patient assistance programs, which Sarepta has already optimized.

Louise Rodino-Klapac clarified that while a traditional approval by a competitor could change the landscape for accelerated approval, Sarepta is designing its trials to support both pathways.

The company will rely on data-driven discussions with the FDA, focusing on the 'best-in-class' potential of their catalytic siRNA mechanism.

Management cautioned that the upcoming MAD data for FSHD is not intended to definitively show functional benefit due to the disease's slow progression and the study's short 6-month follow-up.

The primary goal is to validate the 'biological chain'—proving that high muscle concentration leads to DUX4 knockdown and molecular correction.